GAMMA Investing LLC Lowers Holdings in BioLife Solutions, Inc. $BLFS

GAMMA Investing LLC cut its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 16.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,517 shares of the medical equipment provider’s stock after selling 706 shares during the quarter. GAMMA Investing LLC’s holdings in BioLife Solutions were worth $76,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of BLFS. SG Americas Securities LLC increased its holdings in shares of BioLife Solutions by 21.6% in the 1st quarter. SG Americas Securities LLC now owns 19,136 shares of the medical equipment provider’s stock worth $437,000 after buying an additional 3,405 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of BioLife Solutions by 0.7% during the 1st quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider’s stock valued at $1,901,000 after purchasing an additional 566 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of BioLife Solutions by 13.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider’s stock valued at $1,835,000 after purchasing an additional 8,258 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of BioLife Solutions by 6.2% during the 1st quarter. Principal Financial Group Inc. now owns 259,488 shares of the medical equipment provider’s stock valued at $5,927,000 after purchasing an additional 15,241 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in shares of BioLife Solutions by 37.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 273,329 shares of the medical equipment provider’s stock valued at $6,243,000 after purchasing an additional 74,634 shares during the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at BioLife Solutions

In related news, major shareholder Casdin Partners Master Fund, L sold 500,000 shares of BioLife Solutions stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $24.40, for a total transaction of $12,200,000.00. Following the completion of the transaction, the insider directly owned 6,707,165 shares of the company’s stock, valued at $163,654,826. This trade represents a 6.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Troy Wichterman sold 1,032 shares of BioLife Solutions stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $26.83, for a total transaction of $27,688.56. Following the transaction, the chief financial officer directly owned 184,186 shares of the company’s stock, valued at approximately $4,941,710.38. This trade represents a 0.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,019,198 shares of company stock valued at $23,981,317 in the last three months. Company insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Stephens assumed coverage on shares of BioLife Solutions in a report on Tuesday, July 22nd. They set an “overweight” rating and a $30.00 target price on the stock. Zacks Research raised shares of BioLife Solutions to a “strong-buy” rating in a report on Monday, August 11th. Finally, HC Wainwright reissued a “buy” rating and set a $32.00 price target (up previously from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company’s stock. According to data from MarketBeat.com, BioLife Solutions presently has an average rating of “Buy” and a consensus target price of $31.29.

BioLife Solutions Trading Down 0.8%

NASDAQ:BLFS opened at $25.91 on Friday. The company has a 50-day moving average price of $24.47 and a 200-day moving average price of $23.30. BioLife Solutions, Inc. has a 12 month low of $19.10 and a 12 month high of $29.55. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -215.90 and a beta of 1.95.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.31). BioLife Solutions had a positive return on equity of 0.16% and a negative net margin of 5.39%.The company had revenue of $25.42 million during the quarter, compared to analysts’ expectations of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. Equities analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.